Lumos Diagnostics Holdings Limited (LDX) Q3 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Lumos Diagnostics Investor Briefing to discuss the Q3 FY26 results that were lodged with the ASX yesterday. My name is Jane Lowe, and I'll be your moderator for this session. With us this morning, we have Lumos Diagnostics Chairman, Sam Lanyon. I'll say good morning to you, Sam. Morning, Jane. Good morning. Also CEO and Managing Director, Doug Ward. Afternoon to you. Good morning. Good morning. Good morning, and also CFO Barry Lambert. Good morning, Barry. Good morning, Jane. Good morning, everyone. Good morning. Okay, so the format for today is that Sam, Doug and Barry will walk us through a presentation that was released to ASICS this morning. It should take about half an hour or so, and after that we'll follow along with a Q&A session. We plan to wrap up in about 45 minutes today. If you'd like to ask a question, please click on the Q&A tab in the ribbon at the bottom of your screen. and type your question into the box provided. The webinar is being recorded today as usual. So with that, I'd now like to hand over to Doug, who will get us on the road. Thanks, Doug. Thanks very much, Jane. Really appreciate that. Welcome, everyone. As always, it's always thrilling to speak to our investors and give you an update on the business. We obviously have an updated picture that all three of us will go through. I'll be the lion's share of talking today. What you'll notice is a lot of these slides you may have seen before from the previous investor presentation that we put out on the ASX with some modifications here and there as we did release our quarterly results. So, we've added some of that information into the deck. And certainly, one of the most important things to talk about will be the SPP and a little bit of an update on that process going forward. So,...